Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these patients, no obstructive coronary lesions or stenoses are identified, a condition referred to as angina with no obstructive coronary arteries (ANOCA). This group has been considered to be at higher cardiovascular risk (CVR), mainly due to persistent symptoms, a high burden of cardiovascular risk factors, and the potential presence of microvascular dysfunction or vasospasm. However, long-term evidence comparing their prognosis with that of the general population remains limited.

Pronóstico al año en lesiones ateroscleróticas vs las no ateroscleróticas en pacientes con MINOCA

In this context, the study by Olesen et al. provides long-term follow-up data aimed at evaluating 15-year CVR in patients with ANOCA referred for CAG due to stable angina, compared with a cohort from the general population. Data were obtained from Danish national registries and included patients ≥18 years of age who underwent elective CAG for suspected CSA between 2003 and 2021, in whom the absence of obstructive coronary artery disease (stenosis <50%) and no prior history of myocardial infarction (MI) were documented, thus defining the ANOCA cohort.

Each ANOCA case was matched in a 1:5 ratio by age and sex with individuals from the general population without a history of cardiovascular disease. The maximum follow-up was 15 years, with a mean follow-up of 10.7 years. Evaluated outcomes included MI, ischemic stroke, and all-cause mortality.

During long-term follow-up, the 15-year cumulative incidence of MI was identical in both cohorts (3.5% in ANOCA vs. 3.5% in the general population). The age- and sex-adjusted incidence rate ratio showed a trend toward a lower relative risk in the ANOCA group (IRR 0.89; 95% CI: 0.81–1.00). In contrast, the risk of ischemic stroke was slightly higher in patients with ANOCA (3.7% vs. 2.9%), with an absolute risk difference of 0.8% (95% CI: 0.5–1.2).

Read also: Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents.

All-cause mortality was slightly lower in the ANOCA cohort compared with the general population (25.4% vs. 26.3%), with an absolute difference of −0.9% (95% CI: −1.8 to −0.1) and an IRR of 0.86 (95% CI: 0.83–0.90).

Stratified analyses showed that men and older patients (≥75 years) had more favorable risk profiles compared with the general population. In contrast, a specific subgroup—patients with diffuse non-obstructive coronary artery disease—exhibited a significantly increased risk of MI, ischemic stroke, and mortality, clearly differentiating them from patients with minimal or no coronary disease.

Conclusions

In this population-based observational study, patients with ANOCA exhibited a 15-year risk of MI similar to that of the general population, a slightly lower overall mortality, and a modestly increased risk of ischemic stroke. Importantly, subgroups with higher vulnerability were identified—particularly younger patients, women, and those with diffuse non-obstructive coronary artery disease—highlighting the need for more precise risk stratification in this population.

Original Title: 15-Year Cardiovascular Risk in Patients With Angina Without Obstructive Coronary Arteries.

Reference: Olesen KKW, Madsen M, Würtz M, Thim T, Mortensen MB, Sørensen HT, Maeng M. 15-Year Cardiovascular Risk in Patients With Angina Without Obstructive Coronary Arteries. JACC Cardiovasc Interv. 2025 Dec 22;18(24):3009-3020. doi: 10.1016/j.jcin.2025.09.014. Epub 2025 Nov 14. PMID: 41240023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...